This pattern recognition tool runs Rising and Falling Three Methods recognition and companion studies for INmune Bio. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for INmune Bio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was fourteen with a total number of output elements of forty-seven. The function did not return any valid pattern recognition events for the selected time horizon. The Rising/Falling Three Methods may indicate that INmune Bio has been in a downtrend and is about to experience bullish continuation signal
INmune Bio Technical Analysis Modules
Most technical analysis of INmune Bio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for INmune from various momentum indicators to cycle indicators. When you analyze INmune charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. Market structure and macro sensitivity help explain how INmune Bio behaves across regimes. Cycle exposure remains aligned with broader market trends. INmune Bio has a market cap of 34.03 M, ROE of -1.56%.
Methodology
Unless otherwise specified, financial data for INmune Bio is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. INmune (USA Stocks:INMB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
INmune Bio may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking INmune Bio inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A comprehensive view of INmune Bio starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for INmune Bio Stock. Selected reports below provide context for INmune Stock:
INmune Bio has a market cap of 34.03 M, operating margin of -697.24%, ROE of -1.56%. Review Risk vs Return Analysis for broader portfolio context. This reflects a position in INmune Bio within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Before investing in INmune Stock, review our How to Buy INmune Bio guide for key considerations.Analysis related to INmune Bio should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Earnings Share
-2.08
Revenue Per Share
0.002
Quarterly Revenue Growth
2.571
Return On Assets
-0.51
Return On Equity
-1.56
INmune Bio market price can diverge from book value, the accounting figure shown on INmune balance sheet. INmune Bio's market capitalization is 34.03 M. A P/B ratio of 1.37 indicates the market values INmune Bio above its accounting book value. Enterprise value stands at 8.17 M. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
It is useful to distinguish INmune Bio's value from its trading price, which are computed with different methods. For INmune Bio, key inputs include a P/B ratio of 1.37, ROE of -1.56%, and revenue of 14 K. The quoted price is simply the exchange level where supply meets demand.
Rifka Kats ยท Member of Macroaxis Editorial Board